Clinical data | |
---|---|
Trade names | Tracrium, Acurium |
Other names | Atracurium besylate |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | IV |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 100% (IV) |
Protein binding | 82% |
Metabolism | Hofmann elimination (retro-Michael addition) and ester hydrolysis by nonspecific esterases |
Elimination half-life | 17–21 minutes |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.058.840 |
Chemical and physical data | |
Formula | C65H82N2O18S2 |
Molar mass | 1243.49 g·mol−1 |
3D model (JSmol) | |
Melting point | 85 to 90 °C (185 to 194 °F) |
| |
| |
(what is this?) (verify) |
Atracurium besilate, also known as atracurium besylate, is a medication used in addition to other medications to provide skeletal muscle relaxation during surgery or mechanical ventilation.[1] It can also be used to help with endotracheal intubation but suxamethonium (succinylcholine) is generally preferred if this needs to be done quickly.[1] It is given by injection into a vein.[1] Effects are greatest at about 4 minutes and last for up to an hour.[1]
Common side effects include flushing of the skin and low blood pressure.[1][2] Serious side effects may include allergic reactions; however, it has not been associated with malignant hyperthermia.[1][2] Prolonged paralysis may occur in people with conditions like myasthenia gravis.[1] It is unclear if use in pregnancy is safe for the baby.[1] Atracurium is in the neuromuscular-blocker family of medications and is of the non-depolarizing type.[1] It works by blocking the action of acetylcholine on skeletal muscles.[1]
Atracurium was approved for medical use in the United States in 1983.[1] It is on the World Health Organization's List of Essential Medicines.[3] Atracurium is available as a generic medication.[1]